The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment

被引：0

作者：

Jin, Shanshan

Zhang, Xiaochen

Jia, Yunlu

Dai, Yongchao

Xu, Fengwei

Huang, Yongfeng

Wang, Xun

Wu, Hailong

Shao, Yu

Long, Jinfeng

Zheng, Anjie

Xu, Yuhong

机构：

[1] Hangzhou HighField Biopharmaceut Corp, Hangzhou, Peoples R China

[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[3] Zhejiang Univ, Sch Pharm, Hangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3035

引用

页数：1

共 50 条

[41] Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Moulder, Stacy L.
Borges, Virginia F.
Baetz, Tara
Mcspadden, Tessa
Fernetich, Gina
Murthy, Rashmi K.
Chavira, Renae
Guthrie, Kari
Barrett, Emma
Chia, Stephen K.
CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3529 - 3536
[42] Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Keyaerts, Marleen
Xavier, Catarina
Heemskerk, Johannes
Devoogdt, Nick
Everaert, Hendrik
Ackaert, Chloe
Vanhoeij, Marian
Duhoux, Francois P.
Gevaert, Thierry
Simon, Philippe
Schallier, Denis
Fontaine, Christel
Vaneycken, Ilse
Vanhove, Christian
De Greve, Jacques
Lamote, Jan
Caveliers, Vicky
Lahoutte, Tony
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (01) : 27 - 33
[43] A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
Heymach, John
Opdam, Frans
Barve, Minal
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yamamoto, Noboru
CLINICAL LUNG CANCER, 2023, 24 (02) : e65 - e68
[44] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Opdam, F.
Heymach, J.
Barve, M.
Gibson, N.
Sadrolhefazi, B.
Serra, J.
Yamamoto, N.
ANNALS OF ONCOLOGY, 2022, 33 : S69 - S70
[45] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours.
Agus, D. B.
Terlizzi, E.
Stopfer, P.
Amelsberg, A.
Gordon, M. S.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 97S - 97S
[46] Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab
Jaeger, M.
Ruf, P.
Schoberth, A.
Hess, J.
Lindhofer, H.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[47] In vitro and in vivo activity of a HER2-targeted thorium-227 conjugate (HER2-TTC) in HER2 low expressing and T-DM1/trastuzumab resistant preclinical mouse models
Karlsson, J.
Cruciani, V.
Grant, D.
Ellingsen, C.
Petros, G.
Kristian, A.
Hagemann, U.
Schatz, C.
Bjerke, R.
Ryan, O.
Mumberg, D.
Cuthbertson, A.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E122 - E122
[48] PRECLINICAL CHARACTERIZATION OF D3L-001, A NOVEL BISPECIFIC ANTIBODY THAT ENHANCE PHAGOCYTOSIS AND ERADICATION OF HER2 POSITIVE SOLID TUMOR VIA HER2 AND CD47 DUAL BLOCKADE
Rui, Haopeng
Nie, Siwei
Shao, Jiaxiang
Yang, Xiaofeng
Chen, Jiahao
Wang, Jia
Zheng, Zhiqiang
Lu, Jingtao
Wang, Allison
Hong, Jin
Chen, Xiaosong
Shen, Kunwei
Chen, George
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1431 - A1431
[49] Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)
Overmoyer, B.
Regan, M.
Schlosnagle, E.
Bunnell, C.
Freedman, R.
Tolaney, S.
Chen, W.
Mayer, E.
Partridge, A.
Silver, D.
Winer, E.
CANCER RESEARCH, 2017, 77
[50] Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Opdam, F.
Heymach, J.
Ruiter, G.
Barve, M.
Tu, H.
Wu, Y-L.
Schroeter, L.
Sadrolhefazi, B.
Serra, J.
Yoh, K.
Yamamoto, N.
ANNALS OF ONCOLOGY, 2023, 34

← 1 2 3 4 5 →